secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001193125-23-138934
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Biotherapeutics reports Q1 2023 net loss of $10.2M; IND cleared for SNS-101 Phase 1/2 trial
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities were $95.5M as of March 31, 2023; cash runway into H2 2025.
- Net loss was $10.2M for Q1 2023, compared to $12.4M for Q1 2022; R&D expenses decreased to $5.2M.
- FDA cleared IND for SNS-101 (conditionally active anti-VISTA antibody); Phase 1/2 trial enrollment and dosing expected mid-2023.
- CRADA signed with NCI for VISTA research; SNS-102 and SNS-103 candidate selection on track for 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312523138934/0001193125-23-138934-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312523138934/d456403d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-138934

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer